This Insider Is Grooming the Next Biotech Rocket

This Insider Is Grooming the Next Biotech Winner
By Dr. George Huang
October 2, 2009

In 1999, Wall Street analysts thought Johnson & Johnson had lost it...

The health care conglomerate had a famously stodgy corporate culture. But that year, it dropped $4.9 billion to acquire a little-known antibody developer called Centocor. J&J paid 10.5 times sales – mighty pricey even during the 1999 market euphoria. But J&J knew exactly what kind of value it was getting.

A few years back, when J&J lost patent protection on two of its blockbuster drugs, Remicade, Centocor's autoimmune drug, stepped up to fill the gap. Remicade's gross margins are near 90%. This year, Remicade is on track to generate over $6 billion in worldwide sales. A single year of sales will more than cover J&J's acquisition price.

As the Centocor buyout indicates, J&J is one of the industry's sharpest insiders. But it's hard to profit from J&J's expertise by owning its stock. The company is simply too large. You're not going to double your money in a $165 billion blue chip.

A better bet is to invest in the companies J&J partners with.

Centocor shareholders, for example, ended up collecting about 50% from the buyout. Or take Israeli biotech Omrix... In 2003, J&J snatched up marketing rights to Omrix's technology, which reduces bleeding during surgery. Last year, my colleague Rob Fannon wrote a J&J takeover was likely. And that's exactly what happened... Growth Stock Wire readers could have pocketed a quick 20%.

So who's next on J&J's to buy list? Troubled Irish biotech Elan. And I think this opportunity is even bigger for shareholders...

In July, J&J spent $885 million on an 18.4% stake in Elan. It paid another $500 million to acquire 50% of Elan's Alzheimer's drug candidate. The deal valued shares at over $9. But today, the stock is trading below $7. Due to lousy management and problems with Elan's multiple sclerosis drug, investors have no confidence in the company.

Still, with data from the phase III Alzheimer's trials arriving in 18 months, Elan makes for an interesting speculation. If the results are positive, the drug could easily become a multibillion-dollar seller. And J&J would snatch up the rest of the company in a heartbeat.

Why Stocks Are Moving Higher

What the Best Traders I Know Are Telling Me

If you figure Elan's Alzheimer's drug can pull in $5 billion a year – conservatively – Elan is worth at least $7 billion to J&J right now. That's about $14 a share: 100% above today's price. And the downside risk is limited. After all, J&J values its stake in Elan's existing business at $9 or more.

Judging from its history of successful investments, I agree.

Good investing,

George Huang

Must-read: Why gold stocks could shoot 1,000% higher from here
A little-known insight on the gold market.

This crisis hedge has outperformed gold and silver
If you're worried about the dollar, the economy, or any other problem, buy this today.

Jim Rogers trading tip: This hated asset should rally soon
Buy now to go against the crowd...

•	Investors prepare for higher taxes... muni- bond rally continues as dozens of muni funds make new 52-week highs.
•	Inflation-protected Treasuries fund TIP hits a new high.
•	Small caps suffer huge blow yesterday... Russell 2000 leads indexes lower with 2.6% drop.
•	Gold stocks down big... major gold stock fund (GDX) down 4.5% yesterday.

	Last	Change	52-Wk
S&P 500	1062.98	+1.78%	-12.37%
Oil (USO)	34.51	+1.50%	-59.97%
Gold (GLD)	97.05	+0.05%	+12.02%
Silver (SLV)	15.91	+1.08%	+20.99%
U.S. Dollar	77.11	+0.26%	-0.52%
Euro	1.46	-0.40%	+0.97%
VIX	24.88	-2.85%	-28.38%
HUI	398.09	+0.10%	+20.93%
10-Year Yield	3.30%	-0.03	-0.46

Advertisement

Company	Sym	Industry
Sterlite	SLT	copper
MBIA	MBI	insurance
Flagstone Re	FSR	insurance
CorpBanca	BCA	bank
Wipro	WIT	business services
Solera	SLH	business services
MarkWest Energy	MWE	oil & gas drilling
Evotec	EVTC	pharma
Minas Buena	BVN	gold
Vivo Participacoes	VIV	telecom
Petrobras	PZE	Big Oil
IRSA	IRS	development
Duncan Energy	DEP	pipelines
Clinical Data	CLDA	biotech
Williams-Sonoma	WSM	furnishings retail
Salix Pharma	SLXP	pharma
Liberty Ent	LMDIA	cable TV
Ebix	EBIX	business services
Comp de Bebidas	ABV	brewer
Virgin Media	VMED	cable TV
Odyssey Re	ORH	insurance
Illumina	ILMN	biotech
Discovery Com	DISCA	cable TV
Banco Macro	BMA	bank
Ulta Salon	ULTA	personal services
NET Servicos	NETC	cable TV
iGate	IGTE	IT services
Diamond Foods	DMND	packaged food
Teradyne	TER	semiconductors
Mellanox Tech	MLNX	semiconductors
H&E Equipment	HEES	industrial equip
Credicorp	BAP	bank

Company	Sym	Industry
Osiris Therapeutics	OSIR	biotech
Pacific Capital	PCBC	bank

The Market Has Hit the Moment of Maximum Indecision
October 1, 2009

Commodity Q&A: The Best One-Click Ways to Own Precious Metals
September 30, 2009

How to Know When to Buy Gold Stocks
September 29, 2009

How to Turn a 100% Gain into a 1,400% Gain
September 28, 2009

Weekend Edition: Hundreds of Percent Gains in Housing
September 26, 2009